Xiang Ao

Xiang Ao

Auto-generated profile, based on publicly available information

Xiang Ao

Ginkgo Bioworks, Inc, MA, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2025 in mAbs
Verified
Journal Article
Open access
AAAmmar Arsiwala
Ammar Arsiwala
RBRebecca Bhatt
Rebecca Bhatt
LNLood van Niekerk
Lood van Niekerk
PQPorfirio Quintero-Cadena
Porfirio Quintero-Cadena
XAXiang Ao
Xiang Ao
DBDavid W. Borhani
David W. Borhani
Antibodies must bind their targets with high affinity and specificity to achieve useful therapeutic activity. They must also possess suitable developability properties (e.g. thermostability, solubility, viscosity, polyreactivity) to ensure favorable manufacturing, formulation, and in vivo performance. Both binding and developability properties are inherent to a given antibody amino acid sequence. Identification or selection of antibodies possessing suitable-binding characteristics is now routine, and de novo computational design models, trained on extensive complementarity-determining region sequence and structural data, are rapidly improving. Developability properties, however, remain difficult to predict largely due to insufficient training data, with empirical testing being heavily used to avoid challenges in late-stage antibody development. To fill this gap, we built a high-throughput antibody developability assay platform designed to generate the large datasets needed to train improved machine learning (ML) models. We optimized and automated known developability assays, and developed a robust integrated data analytics pipeline. Here, we report data on 246 antibodies - representing 106 approved, 135 clinical-stage, and 5 preregistration/withdrawn molecules - across a panel of 10 developability assays, in a "tidy data" format suitable for AI/ML modeling. We used these data to develop an XGBoost ML model that better predicts similarity to approved antibodies compared to conventional use of developability warning thresholds. Additionally, we confirm that preliminary predictive models do improve with more training data. Our high-throughput PROPHET-Ab platform enables data generation at the scale needed to develop improved ML models to predict antibody developability.

22 February 2026 in mAbs
Verified
Journal Article
Open access
LNLood van Niekerk
Lood van Niekerk
JMJoshua Moller
Joshua Moller
SRSeth Ritter
Seth Ritter
PQPorfirio Quintero-Cadena
Porfirio Quintero-Cadena
RCRich Cohen
Rich Cohen
AAAmmar Arsiwala
Ammar Arsiwala
Monoclonal antibodies (mAbs) are among the most successful therapeutic modalities, with over 200 marketed products and nearly 1400 candidates in clinical development.1 While high-affinity binding r...

19 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SRSeth Ritter
Seth Ritter
LRLaura Rand
Laura Rand
SKSai Karthick
Sai Karthick
TBTim Bloomingdale
Tim Bloomingdale
ASAlexander Smith
Alexander Smith
AAAmmar Arsiwala
Ammar Arsiwala
Bispecific antibodies deliver functional outcomes that monospecific antibodies cannot, yet emergent self-association, polyreactivity, and aggregation often degrade their developability relative to their parental arms. Whether bispecific developability inherits from the parents or is driven by the format has not been tested at scale. We characterized 160 bispecific antibodies and their 65 parental arms on a uniform knobs-into-holes CrossMab IgG1 scaffold across 10 assays on the PROPHET-Ab high-throughput platform. Bispecific developability separates into three classes of inheritance. Hydrophobicity and surface charge inherit cleanly from the parents (Spearman ρ ≈ 0.85 to 0.95), so parental-level screening predicts bispecific fate. Self-association and polyreactivity inherit partially (ρ ≈ 0.60 to 0.88), with mechanistically interpretable emergent outliers driven in part by Fv-Fv charge complementarity and a parental biophysical ceiling on the hydrophobicity (HIC) by surface-charge (HAC) plane. Thermostability is poorly predicted from parental antibodies (ρ < 0.4), so it requires bispecific-level testing. The class framework yields actionable selection rules: triage hydrophobicity and charge at the parental level, avoid pairing two high-HIC x high-HAC arms, pair opposite-sign Fv charges to suppress self-association but re-validate at the formulation buffer, and measure thermostability on the bispecific itself. This work charts a tractable path from monospecific sequence to bispecific developability prediction. Significance: Bispecific antibodies are a fast-growing therapeutic class, yet the rational design of well-behaving bispecific antibodies from validated monospecific antibody building blocks remains challenging. A key bottleneck is the lack of comprehensive, high-quality public datasets linking parental antibody developability properties to corresponding bispecific antibody developability properties. We address this gap by releasing a dataset comprising 160 bispecific antibodies and the 65 parental monospecific antibodies profiled in 10 developability assays. The data show that bispecific antibody developability is complex. Some properties are easily predictable from the parents, whereas others emerge in the bispecific format or from the bispecific format itself. The factors that govern each property can be identified empirically and used to make practical selection decisions. The mechanistic explanations and predictive models reported here establish a compact set of actionable rules. Together, they define a framework for using computational pipelines to convert monospecific antibodies into bispecific antibodies with drug-like developability properties, enabling faster and more effective generation of high-quality bispecific antibodies for diverse therapeutic applications.

21 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JMJoshua Moller
Joshua Moller
SRSeth Ritter
Seth Ritter
LRLaura Rand
Laura Rand
ASAlexander Smith
Alexander Smith
YPYolaine Pierre
Yolaine Pierre
AAAmmar Arsiwala
Ammar Arsiwala
The VHH-Fc antibody scaffold is an emerging therapeutic modality. No public large-scale, standardized developability VHH-Fc dataset exists. Filling that gap, we introduce GDPa5, a 160-member VHH-Fc library profiled across 10 biophysical assays on the PROPHET-Ab platform. Cross format models trained on the developability properties of 559 IgGs outperformed intra-format models trained on GDPa5 alone, which is an advantage driven by the larger scale of standardized IgG data rather than by format. The most accurately predicted properties were heparin binding (HAC, Spearman ρ=0.82), hydrophobicity (HIC, ρ=0.63), and self-association (AC-SINS, ρ=0.62), all of which are largely governed by antibody surface properties. Tabular neural networks (TabICLv2, TabPFN v2.5), applied here for the first time to antibody developability prediction, outperformed conventional modeling approaches. Adding experimental HIC and HAC measurements as model inputs improved prediction of the more complex polyreactivity liability (PR-CHO, Δρ = +0.10), supporting a tiered assay strategy that extends predictive performance while limiting experimental burden. We demonstrate through this work that IgG-trained models are a practical, data-efficient starting point for VHH-Fc developability prediction. Significance: The therapeutic antibody landscape is rapidly diversifying beyond conventional IgG scaffolds, yet developability prediction tools have not kept pace. Format-specific training data are scarce for emerging scaffolds; whether models trained on IgGs can predict the developability properties of other scaffolds has not been systematically evaluated. In this work, we present GDPa5, a 160-member VHH-Fc developability dataset, and demonstrate that models trained exclusively on IgG data can predict VHH-Fc developability without VHH-Fc-specific training. The GDPa5 dataset and the predictive power of tabular neural networks establish a data-efficient modeling framework broadly applicable to emerging antibody formats.